Incyte - INCY Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $79.94
Forecasted Upside: 47.99%
Number of Analysts: 19
Breakdown:
1 Sell Ratings
10 Hold Ratings
8 Buy Ratings
0 Strong Buy Ratings

^$54.02 As of 12/1/2023 01:00 AM ET

▼ -0.32 (-0.59%)

1 month | 3 months | 12 months

Get New Incyte Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for INCY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INCY

^$79.94

▲ +47.99% Upside Potential

This price target is based on 19 analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is $79.94, with a high forecast of $100.00 and a low forecast of $61.00. The average price target represents a 47.99% upside from the last price of $54.02.

Current Consensus is Hold

The current consensus among 19 contributing investment analysts is to hold stock in Incyte. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
8 buy ratings
10 hold ratings
1 sell ratings

Ratings as of

6/11/2022

0 strong buy ratings
8 buy ratings
10 hold ratings
1 sell ratings

Ratings as of

9/9/2022

0 strong buy ratings
8 buy ratings
10 hold ratings
1 sell ratings

Ratings as of

12/8/2022

0 strong buy ratings
8 buy ratings
10 hold ratings
1 sell ratings

Ratings as of

3/8/2023

0 strong buy ratings
8 buy ratings
10 hold ratings
1 sell ratings

Ratings as of

6/6/2023

0 strong buy ratings
8 buy ratings
10 hold ratings
1 sell ratings

Ratings as of

9/4/2023

0 strong buy ratings
8 buy ratings
10 hold ratings
1 sell ratings

Ratings as of

11/3/2023

0 strong buy ratings
8 buy ratings
10 hold ratings
1 sell ratings

Ratings as of

12/3/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
11/29/2023	Truist Financial	Reiterated Rating	Buy ➝ Buy	$91.00	Low
11/21/2023	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$98.00 ➝ $65.00	Low
11/2/2023	The Goldman Sachs Group	Lower Target	Buy ➝ Buy	$114.00 ➝ $98.00	Low
11/1/2023	Royal Bank of Canada	Lower Target	Sector Perform ➝ Sector Perform	$74.00 ➝ $63.00	Low
11/1/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$74.00 ➝ $64.00	Low
9/21/2023	Truist Financial	Reiterated Rating	Buy ➝ Buy	$91.00	Low
8/2/2023	Oppenheimer	Reiterated Rating	Outperform ➝ Outperform	$92.00	Low
8/2/2023	BMO Capital Markets	Lower Target	Market Perform ➝ Market Perform	$70.00 ➝ $68.00	Low
8/2/2023	JMP Securities	Reiterated Rating	Market Outperform ➝ Market Outperform	$93.00	Low
8/2/2023	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$74.00	N/A
8/2/2023	Royal Bank of Canada	Boost Target	Sector Perform ➝ Sector Perform	$70.00 ➝ $73.00	N/A
8/2/2023	Stifel Nicolaus	Boost Target	Hold ➝ Hold	$73.00 ➝ $76.00	Low
8/2/2023	Truist Financial	Lower Target	Buy ➝ Buy	$100.00 ➝ $91.00	Low
7/25/2023	JMP Securities	Reiterated Rating	Market Outperform ➝ Market Outperform	$93.00	Low
7/25/2023	Citigroup	Initiated Coverage	Buy	$82.00	Low
7/20/2023	Morgan Stanley	Reiterated Rating	Underweight ➝ Underweight	$74.00	Low
5/4/2023	JMP Securities	Lower Target		$113.00 ➝ $93.00	Low
5/4/2023	Bank of America	Downgrade	Buy ➝ Neutral	$84.00	Low
5/3/2023	VNET Group	Reiterated Rating	Maintains		Low
5/3/2023	BMO Capital Markets	Lower Target		$75.00 ➝ $70.00	Low
5/3/2023	Royal Bank of Canada	Lower Target		$79.00 ➝ $70.00	Low
5/3/2023	Stifel Nicolaus	Lower Target		$80.00 ➝ $73.00	Low
5/3/2023	Mizuho	Lower Target		$95.00 ➝ $82.00	Low
4/19/2023	JMP Securities	Reiterated Rating	Market Outperform	$113.00	Low
4/12/2023	Morgan Stanley	Boost Target	Equal Weight	$76.00 ➝ $77.00	Low
4/10/2023	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$81.00 ➝ $79.00	Low
3/28/2023	JMP Securities	Reiterated Rating	Market Outperform	$113.00	Low
3/24/2023	SVB Securities	Upgrade	Underperform ➝ Market Perform	$61.00	Low
3/20/2023	William Blair	Reiterated Rating	Outperform		Low
3/7/2023	JMP Securities	Reiterated Rating	Buy	$113.00	Low
2/16/2023	Credit Suisse Group	Boost Target	Buy	$95.00 ➝ $100.00	Low
2/13/2023	JMP Securities	Reiterated Rating	Market Outperform	$113.00	Low
2/8/2023	Piper Sandler	Reiterated Rating	Overweight	$100.00	Low
2/8/2023	Mizuho	Reiterated Rating	Neutral	$95.00	Low
2/8/2023	JPMorgan Chase & Co.	Lower Target	Neutral	$82.00 ➝ $80.00	Low
2/8/2023	SVB Leerink	Reiterated Rating	Underperform	$63.00	Low
2/8/2023	Cowen	Boost Target	Outperform	$95.00 ➝ $100.00	Low
1/31/2023	Piper Sandler	Initiated Coverage	Overweight	$100.00	Low
1/3/2023	Wells Fargo & Company	Boost Target	Equal Weight	$72.00 ➝ $75.00	Low
11/2/2022	Morgan Stanley	Boost Target	Equal Weight	$76.00 ➝ $77.00	Low
11/2/2022	Royal Bank of Canada	Boost Target	Outperform	$77.00 ➝ $82.00	Low
10/24/2022	JPMorgan Chase & Co.	Lower Target	Neutral	$86.00 ➝ $80.00	Low
10/18/2022	Wells Fargo & Company	Lower Target	Equal Weight	$76.00 ➝ $75.00	Low
9/22/2022	Evercore ISI	Downgrade	In-Line		Low
8/9/2022	Guggenheim	Downgrade	Neutral		Low
8/3/2022	Morgan Stanley	Lower Target	Equal Weight	$77.00 ➝ $76.00	N/A
8/3/2022	Evercore ISI	Downgrade	Outperform ➝ Inline	$90.00 ➝ $78.00	Low
8/3/2022	Oppenheimer	Lower Target		$109.00 ➝ $98.00	Low
8/3/2022	Guggenheim	Downgrade	Buy ➝ Neutral		Low
7/28/2022	Wells Fargo & Company	Initiated Coverage	Equal Weight	$76.00	Low
7/20/2022	SVB Leerink	Boost Target	Underperform	$58.00 ➝ $63.00	Low
5/3/2022	Stifel Nicolaus	Boost Target		$75.00 ➝ $77.00	Low
4/20/2022	Morgan Stanley	Boost Target	Equal Weight	$73.00 ➝ $76.00	Low
2/9/2022	SVB Leerink	Downgrade	Market Perform ➝ Underperform	$60.00 ➝ $56.00	Low
2/2/2022	Morgan Stanley	Lower Target	Equal Weight	$77.00 ➝ $76.00	Low
1/18/2022	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$78.00 ➝ $90.00	Medium
1/3/2022	Guggenheim	Lower Target		$118.00 ➝ $104.00	High
12/17/2021	JMP Securities	Reiterated Rating	Buy	$108.00	High
11/18/2021	BMO Capital Markets	Initiated Coverage	Market Perform	$75.00	Low
11/4/2021	JMP Securities	Lower Target	Market Outperform	$124.00 ➝ $108.00	High
11/3/2021	Oppenheimer	Lower Target	Outperform	$110.00 ➝ $109.00	High
10/15/2021	Cantor Fitzgerald	Lower Target	Neutral	$104.00 ➝ $79.00	Low
10/4/2021	Truist Financial	Lower Target	Buy	$120.00 ➝ $95.00	Medium
9/24/2021	JMP Securities	Reiterated Rating	Buy	$124.00	Low
9/23/2021	Morgan Stanley	Lower Target	Equal Weight	$85.00 ➝ $80.00	Low
9/23/2021	Royal Bank of Canada	Lower Target	Sector Perform	$91.00 ➝ $86.00	Low
8/4/2021	SVB Leerink	Lower Target	Underperform	$70.00 ➝ $67.00	Low
7/20/2021	Benchmark	Upgrade	Hold ➝ Buy	$89.00	Medium
6/25/2021	Royal Bank of Canada	Lower Target	Sector Perform	$92.00 ➝ $88.00	Low
6/15/2021	William Blair	Reiterated Rating	Outperform		Low
6/15/2021	SVB Leerink	Reiterated Rating	Sell		Low
5/5/2021	Morgan Stanley	Lower Target	Equal Weight	$86.00 ➝ $85.00	Low
4/5/2021	Morgan Stanley	Lower Target	Equal Weight	$93.00 ➝ $86.00	Low
2/10/2021	Morgan Stanley	Lower Target	Equal Weight	$97.00 ➝ $93.00	Low
2/10/2021	SVB Leerink	Downgrade	Market Perform ➝ Underperform	$89.00 ➝ $70.00	Low
1/7/2021	Truist Financial	Initiated Coverage	Buy	$120.00	N/A
1/4/2021	Guggenheim	Upgrade	Neutral ➝ Buy		N/A
11/9/2020	Morgan Stanley	Lower Target	Equal Weight	$103.00 ➝ $97.00	High
11/6/2020	BMO Capital Markets	Lower Target	Market Perform	$94.00 ➝ $87.00	Medium
11/6/2020	Royal Bank of Canada	Lower Target	Sector Perform	$96.00 ➝ $86.00	Medium
10/15/2020	Bank of America	Lower Target	Buy	$113.00 ➝ $110.00	Low
10/13/2020	Morgan Stanley	Boost Target	Equal Weight	$100.00 ➝ $103.00	Low
8/9/2020	Cowen	Reiterated Rating	Buy		Medium
8/6/2020	BMO Capital Markets	Boost Target	Market Perform	$90.00 ➝ $94.00	Low
8/6/2020	Credit Suisse Group	Lower Target	Neutral	$100.00 ➝ $97.00	Low
8/6/2020	Morgan Stanley	Boost Target	Equal Weight	$95.00 ➝ $100.00	Low
8/4/2020	Mizuho	Initiated Coverage	Hold	$79.00 ➝ $95.00	Medium
8/4/2020	SVB Leerink	Boost Target	Market Perform	$86.00 ➝ $87.00	Low
8/3/2020	Royal Bank of Canada	Boost Target	Sector Perform	$91.00 ➝ $92.00	High
7/28/2020	JPMorgan Chase & Co.	Reiterated Rating	Hold	$99.00	Low
7/24/2020	William Blair	Reiterated Rating	Buy		Low
7/20/2020	Credit Suisse Group	Boost Target	Neutral	$88.00 ➝ $100.00	High
7/17/2020	Oppenheimer	Reiterated Rating	Buy	$121.00	High
6/17/2020	William Blair	Reiterated Rating	Buy		Low
6/16/2020	Benchmark	Initiated Coverage	Hold		Low
6/15/2020	Oppenheimer	Initiated Coverage	Buy	$120.00	Medium
6/4/2020	Argus	Boost Target	Buy	$92.00 ➝ $124.00	High
5/26/2020	The Goldman Sachs Group	Downgrade	Conviction-Buy ➝ Buy		High
5/19/2020	Cantor Fitzgerald	Boost Target	Neutral	$83.00 ➝ $100.00	Medium
5/12/2020	Morgan Stanley	Boost Target	Equal Weight	$94.00 ➝ $95.00	High
5/6/2020	Credit Suisse Group	Reiterated Rating	Hold	$88.00	Low
5/6/2020	BMO Capital Markets	Boost Target	Market Perform	$74.00 ➝ $90.00	Low
5/6/2020	Nomura	Reiterated Rating	Buy	$116.00	Low
5/6/2020	Oppenheimer	Boost Target	Outperform	$112.00 ➝ $120.00	Medium
5/6/2020	Royal Bank of Canada	Boost Target	In-Line ➝ Sector Perform	$81.00 ➝ $91.00	Medium
5/5/2020	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$89.00 ➝ $99.00	Medium
4/29/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$94.00	Medium
4/21/2020	Oppenheimer	Boost Target	Outperform	$90.00 ➝ $112.00	Medium
4/20/2020	Piper Sandler	Boost Target	Overweight	$95.00 ➝ $110.00	Low
4/19/2020	Mizuho	Reiterated Rating	Hold	$79.00	Low
4/9/2020	William Blair	Reiterated Rating	Buy		Low
4/8/2020	Royal Bank of Canada	Reiterated Rating	Hold	$81.00	Medium
4/8/2020	Nomura Securities	Reiterated Rating	Buy	$116.00	Medium
4/7/2020	Oppenheimer	Boost Target	Outperform	$85.00 ➝ $90.00	Low
4/6/2020	Piper Sandler	Reiterated Rating	Buy		High
4/1/2020	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$83.00 ➝ $90.00	Medium
3/25/2020	Oppenheimer	Lower Target		$99.00 ➝ $85.00	High
3/24/2020	William Blair	Initiated Coverage	Outperform		High
3/18/2020	Royal Bank of Canada	Reiterated Rating	Hold	$81.00	Medium
3/13/2020	Bank of America	Upgrade	Neutral ➝ Buy	$83.00	High
3/11/2020	Credit Suisse Group	Lower Target	Neutral	$86.00 ➝ $81.00	Medium
2/19/2020	Piper Sandler	Reiterated Rating	Buy		Low
2/19/2020	Nomura Securities	Boost Target	Buy	$111.00 ➝ $116.00	Low
2/19/2020	Cowen	Reiterated Rating	Buy		Low
2/16/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy	$89.00	Low
2/16/2020	Evercore ISI	Reiterated Rating	Buy	$92.00	Low
2/13/2020	Mizuho	Reiterated Rating	Hold	$79.00	High
2/4/2020	Bank of America	Reiterated Rating	Neutral	$82.00	Low
1/30/2020	Royal Bank of Canada	Reiterated Rating	Hold	$80.00	Medium
1/27/2020	Evercore ISI	Reiterated Rating	Buy	$92.00	Low
1/23/2020	Cantor Fitzgerald	Boost Target	Neutral	$65.00 ➝ $83.00	Low
1/14/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		High
1/14/2020	JMP Securities	Reiterated Rating	Outperform	$121.00	High
1/13/2020	Cowen	Reiterated Rating	Buy		High
1/6/2020	Royal Bank of Canada	Reiterated Rating	Hold ➝ Neutral		High
1/6/2020	Morgan Stanley	Lower Target	Equal Weight	$89.00 ➝ $83.00	Low
1/3/2020	Royal Bank of Canada	Lower Target		$80.00	Medium
1/3/2020	The Goldman Sachs Group	Lower Target	Buy	$122.00 ➝ $107.00	High
1/3/2020	Credit Suisse Group	Lower Target	Neutral	$90.00 ➝ $86.00	High
1/3/2020	Oppenheimer	Lower Target	Outperform	$100.00 ➝ $96.00	High
1/3/2020	BMO Capital Markets	Lower Target	Market Perform	$85.00 ➝ $74.00	High
1/3/2020	Citigroup	Reiterated Rating	Outperform	$100.00 ➝ $96.00	High
1/3/2020	JMP Securities	Lower Target	Market Outperform	$110.00 ➝ $99.00	High
1/3/2020	Cantor Fitzgerald	Lower Target	Neutral	$75.00 ➝ $65.00	High
1/2/2020	Mizuho	Downgrade	Buy ➝ Neutral	$98.00 ➝ $79.00	High
1/2/2020	Piper Sandler Companies	Reiterated Rating	Buy	$95.00	High
1/2/2020	Cowen	Reiterated Rating	Buy		High
1/2/2020	Guggenheim	Downgrade	Buy ➝ Neutral		Medium
12/18/2019	Mizuho	Reiterated Rating	Buy	$98.00	Low
11/27/2019	Mizuho	Reiterated Rating	Buy	$98.00	Low
10/29/2019	Mizuho	Reiterated Rating	Buy	$95.00	Medium
10/2/2019	Mizuho	Initiated Coverage	Buy	$95.00	Medium
9/30/2019	JMP Securities	Boost Target	Buy ➝ Market Outperform	$107.00 ➝ $110.00	Medium
9/27/2019	Cowen	Reiterated Rating	Buy		Low
9/27/2019	Guggenheim	Set Target	Buy	$101.00	Low
9/12/2019	BMO Capital Markets	Initiated Coverage	Market Perform	$85.00	High
9/5/2019	Morgan Stanley	Boost Target	Equal ➝ Equal Weight	$82.00 ➝ $87.00	High
9/5/2019	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$85.00 ➝ $100.00	Medium
9/5/2019	JMP Securities	Upgrade	Market Perform ➝ Outperform	$107.00	Medium
8/4/2019	Cowen	Reiterated Rating	Buy		Low
7/31/2019	SVB Leerink	Set Target	Hold	$90.00	Medium
7/31/2019	Nomura Securities	Boost Target	Buy	$100.00 ➝ $111.00	Low
7/31/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$91.00	Low
7/31/2019	Morgan Stanley	Boost Target	Equal Weight	$81.00 ➝ $82.00	Low
6/17/2019	Piper Sandler Companies	Reiterated Rating	Buy		Low
5/27/2019	Cowen	Reiterated Rating	Buy		Low
5/20/2019	Credit Suisse Group	Initiated Coverage	Neutral	$75.00	Medium
5/15/2019	Piper Sandler Companies	Boost Target	Overweight	$85.00 ➝ $95.00	Low
5/15/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$90.00	Low
5/3/2019	Barclays	Downgrade	Overweight ➝ Equal Weight	$90.00 ➝ $82.00	High
4/30/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		High
4/22/2019	Cowen	Reiterated Rating	Buy		Low
4/14/2019	Barclays	Reiterated Rating	Buy	$90.00	High
4/10/2019	Stifel Nicolaus	Initiated Coverage	Hold	$82.00 ➝ $82.00	Medium
4/7/2019	Oppenheimer	Set Target	Hold	$85.00	Low
4/3/2019	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$89.00	High
2/25/2019	Argus	Boost Target	Buy ➝ Buy	$83.00 ➝ $98.00	Low
2/15/2019	Raymond James	Set Target	Buy	$100.00	Low
2/15/2019	Royal Bank of Canada	Boost Target	Outperform	$89.00	High
2/11/2019	JMP Securities	Reiterated Rating	Hold		Low
2/5/2019	SunTrust Banks	Boost Target	Buy	$90.00	Low
1/24/2019	William Blair	Upgrade	Market Perform ➝ Outperform	$85.00 ➝ $100.00	Low
1/23/2019	Gabelli	Upgrade	Hold ➝ Buy	$105.00	Medium
1/16/2019	UBS Group	Downgrade	Buy ➝ Neutral	$75.00 ➝ $82.00	Medium
1/15/2019	The Goldman Sachs Group	Upgrade	Buy ➝ Conviction-Buy		High
1/10/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
1/3/2019	Guggenheim	Upgrade	Neutral ➝ Buy		High
12/9/2018	Cowen	Reiterated Rating	Buy		Low
12/3/2018	Cowen	Reiterated Rating	Buy		High

(Data available from 12/3/2018 forward)

News Sentiment Rating

0.41 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

23 very positive mentions
14 positive mentions
2 negative mentions
2 very negative mentions

Mentions as of

5/7/2023

16 very positive mentions
10 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

6/6/2023

12 very positive mentions
6 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

7/6/2023

25 very positive mentions
19 positive mentions
1 negative mentions
2 very negative mentions

Mentions as of

8/5/2023

8 very positive mentions
3 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

9/4/2023

16 very positive mentions
8 positive mentions
0 negative mentions
3 very negative mentions

Mentions as of

10/4/2023

9 very positive mentions
24 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

11/3/2023

4 very positive mentions
13 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

12/3/2023

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Today's Range

Now: $54.02

$53.62

$54.61

50 Day Range

MA: $55.35

$52.16

$59.28

52 Week Range

Now: $54.02

$50.27

$86.29

Volume

1,882,507 shs

Average Volume

1,653,219 shs

Market Capitalization

$12.11 billion

P/E Ratio

28.58

Dividend Yield

N/A

Beta

0.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Incyte?: The following equities research analysts have issued research reports on Incyte in the last twelve months: Bank of America Co., BMO Capital Markets, Citigroup Inc., Cowen Inc, Credit Suisse Group AG, JMP Securities, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, SVB Securities, The Goldman Sachs Group, Inc., TheStreet, Truist Financial Co., VNET Group, Inc., Wells Fargo & Company, and William Blair.
View the latest analyst ratings for INCY.
What is the current price target for Incyte?: 18 Wall Street analysts have set twelve-month price targets for Incyte in the last year. Their average twelve-month price target is $79.94, suggesting a possible upside of 48.0%. Cowen Inc has the highest price target set, predicting INCY will reach $100.00 in the next twelve months. SVB Securities has the lowest price target set, forecasting a price of $61.00 for Incyte in the next year.
View the latest price targets for INCY.
What is the current consensus analyst rating for Incyte?: Incyte currently has 1 sell rating, 10 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in INCY, but not buy more shares or sell existing shares.
View the latest ratings for INCY.
What other companies compete with Incyte?: Other companies that are similar to Incyte include Charles River Laboratories International, Medpace, ICON Public, IQVIA and Exact Sciences. Learn More about companies similar to Incyte.
How do I contact Incyte's investor relations team?: Incyte's physical mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company's listed phone number is (302) 498-6700 and its investor relations email address is [email protected]. The official website for Incyte is www.incyte.com. Learn More about contacing Incyte investor relations.

Incyte - INCY Stock Price Target and Predictions

Analyst Price Target for INCY

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.41 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Incyte?

What is the current price target for Incyte?

What is the current consensus analyst rating for Incyte?

What other companies compete with Incyte?

How do I contact Incyte's investor relations team?